GX-03 / Turn Therap - LARVOL DELTA

Turn Therapeutics’ GX-03 Technology Named as One of “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine (GlobeNewswire) - "'We are working diligently to bring our proprietary pipeline of therapeutics to market and look forward to announcing topline data from our lead program in severe eczema in early 2026.'"

Clinical data • Commercial • Atopic Dermatitis • Dermatology

Turn Therapeutics Announces Positive In-Vivo Data for Non-Melanoma Skin Cancer Candidate (PRNewswire) - "Turn Therapeutics...announced positive in-vivo data for its therapeutic candidate (GX-03) as a non-invasive treatment for Basal Cell Carcinoma (BCC)....In a large human tumor xenograft study over 30 days, GX-03 showed statistically significant inhibition of tumor growth compared to placebo. The study also incorporated a standard of care chemotherapeutic comparator arm, Fluorouracil (5-FU). In the study, GX-03 inhibited tumor growth in a numerically significant manner as compared to 5-FU, as well."

Preclinical • Basal Cell Carcinoma • Non-melanoma Skin Cancer • Oncology • Skin Cancer • Solid Tumor